⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868756 | 0.80 | CYP19A1 (0.34) | — | |
| SCHEMBL7500349 | 0.75 | CYP19A1 (0.30) | — | |
| SCHEMBL583416 | 0.74 | ALDH1A1 (0.31) | — | |
| SCHEMBL16743125 | 0.74 | CYP2D6 (0.34) | — | |
| SCHEMBL8103731 | 0.73 | P2RX4 (0.31) | — | |
| SCHEMBL929320 | 0.73 | — | — | |
| SCHEMBL11044791 | 0.72 | — | — | |
| SCHEMBL8713295 | 0.71 | PKM (0.31) | — | |
| SCHEMBL584337 | 0.71 | ALDH1A1 (0.33) | — | |
| SCHEMBL1617835 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268778-B2 | Flavivirus NS5A proteins for the treatment of HIV | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-7994114-B2 | Modulating stroma-cell-derived-factor (SDF-1) receptor activity in hematopoietic stem cells, hematopoietic progenitor cells, primitive granulocytes, primitive erythroid cells, leukocytes, and neutrophils; reducing ability to act as substrate to amino/carboxypeptidases | BRITISH CANADIAN BIOSCIENCES CORP (CA) | 2011-08-09 | — | — | US | disclosed |
| US-20100143454-A1 | Flavivirus NS5A Proteins For the Treatment of HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-10 | — | — | US | disclosed |
| CN-101200502-A | Design of interferon-inducible protein-10 (IP10 or CXCL10) chemokine analogs for the treatment of human diseases | CHEMOKINE THERAPEUTICS CORP (CA) | 2008-06-18 | — | — | CN | disclosed |
| US-7378098-B2 | CXC chemokine receptor 4 agonist peptides | THE UNIVERSITY OF BRITISH COLUMBIA | 2008-05-27 | — | — | US | disclosed |
| EP-1882698-A1 | Design of interferon-inducible protein-10 (IP10 or CXCL10) chemokine analogs for the treatment of human diseases | Chemokine Therapeutics Corp. (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20070275892-A9 | Novel chemokine mimetics synthesis and their use | CHEMOKINE THERAPEUTICS CORP. | 2007-11-29 | — | — | US | disclosed |
| EP-1720910-A4 | METHOD AND COMPOSITION FOR ANGIOGENESIS INHIBITION | CANCERVAX CORP (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1536834-A4 | DESIGN OF CHEMOKINE ANALOGS FOR THE TREATMENT OF HUMAN DISEASES | CHEMOKINE THERAPEUTICS CORP (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1834961-A2 | Design of chemokine analogs for the treatment of human diseases | Chemokine Therapeutics Corp. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7091310-B2 | Chemokine analogs for the treatment of human disease | CHEMOKINE THERAPEUTICS CORPORATION (CA) | 2006-08-15 | — | — | US | disclosed |
| US-20050271650-A1 | Method and composition for angiogenesis inhibition | CELLMATRIX, INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005079508-A2 | METHOD AND COMPOSITION FOR ANGIOGENESIS INHIBITION | CANCERVAX CORPORATION (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1536834-A2 | DESIGN OF CHEMOKINE ANALOGS FOR THE TREATMENT OF HUMAN DISEASES | Chemokine Therapeutics Corp. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050059584-A1 | Stroma cell-derived factor (SDF-1) and/or SDF-1/macrophage inflammatory protein (MIP1) alpha hybrid analogs; for increasing hemocrit, mobilizing stem cells, vaccine production, or gene therapy; for mobilizing intracellular calcium and leukocytes | CHEMOKINE THERAPEUTICS CORP. | 2005-03-17 | — | — | US | disclosed |
| US-20040197303-A1 | Design of chemokine analogs for the treatment of human disease | BRITISH CANADIAN BIOSCIENCES CORP. (CA) | 2004-10-07 | — | — | US | disclosed |
| EP-1276493-B1 | CXCR4 AGONIST TREATMENT OF HEMATOPOIETIC CELLS | UNIV BRITISH COLUMBIA (CA) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004024088-A2 | DESIGN OF CHEMOKINE ANALOGS FOR THE TREATMENT OF HUMAN DISEASES | CHEMOKINE THERAPEUTICS CORP. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20030148940-A1 | CXCR4 agonist treatment of hematopoietic cells | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2003-08-07 | — | — | US | disclosed |
| US-20020165123-A1 | CXCR4 agonist treatment of hemapoietic cells | CHEMOKINE THERAPEUTICS CORPORATION (CA) | 2002-11-07 | — | — | US | disclosed |